Excessive transforming growth factor-β 2 signaling is a common mechanism in osteogenesis imperfecta

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 670-675

  Grafe, Ingo ^a   Yang, Tao ^a   Alexander, Stefanie ^a   Homan, Erica P ^a   Lietman, Caressa ^a,b   Jiang, Ming Ming ^a   Bertin, Terry ^a   Munivez, Elda ^a   Chen, Yuqing ^a   Dawson, Brian ^a,b   Ishikawa, Yoshihiro ^c,d   Weis, Mary Ann ^e   Sampath, T Kuber ^f   Ambrose, Catherine ^g   Eyre, David ^e   Bächinger, Hans Peter ^c,d   Lee, Brendan ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f Genzyme   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DECORIN; NEUTRALIZING ANTIBODY; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); FEMALE; LUNG DISEASE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

MUS;

ANALYSIS OF VARIANCE; ANIMALS; COLLAGEN TYPE I; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; IMMUNOBLOTTING; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOGENESIS IMPERFECTA; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TRANSFORMING GROWTH FACTOR BETA; X-RAY MICROTOMOGRAPHY;

EID: 84902207758     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3544     Document Type: Article

References (45)

1. Rauch, F. & Glorieux, F.H. Osteogenesis imperfecta. Lancet 363, 1377-1385 (2004). (Pubitemid 38529880)
2. Baldridge, D. et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum. Mutat. 29, 1435-1442 (2008). (Pubitemid 352774897)
3. Markmann, A., Hausser, H., Schonherr, E. & Kresse, H. Influence of decorin expression on transforming growth factor-β-mediated collagen gel retraction and biglycan induction. Matrix Biol. 19, 631-636 (2000).
4. Takeuchi, Y., Kodama, Y. & Matsumoto, T. Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J. Biol. Chem. 269, 32634-32638 (1994).
5. Morello, R. et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 127, 291-304 (2006). (Pubitemid 44604299)
6. Mizuno, K., Peyton, D.H., Hayashi, T., Engel, J. & Bächinger, H.P. Effect of the -Gly-3(S)-hydroxyprolyl-4(R)-hydroxyprolyl- tripeptide unit on the stability of collagen model peptides. FEBS J. 275, 5830-5840 (2008).
7. Homan, E.P. et al. Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues. PLoS Genet. 10, e1004121 (2014).
8. Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009).
9. Yang, T. et al. E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment. Proc. Natl. Acad. Sci. USA 110, 7336-7341 (2013).
10. Dallas, S.L. et al. Characterization and autoregulation of latent transforming growth factor β (TGF β) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF β-binding protein. J. Biol. Chem. 269, 6815-6821 (1994).
11. Hering, S. et al. TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples. Exp. Clin. Endocrinol. Diabetes 109, 217-226 (2001). (Pubitemid 32577689)
12. Oreffo, R.O., Mundy, G.R., Seyedin, S.M. & Bonewald, L.F. Activation of the bone-derived latent TGF β complex by isolated osteoclasts. Biochem. Biophys. Res. Commun. 158, 817-823 (1989). (Pubitemid 19075997)
13. Hildebrand, A. et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem. J. 302, 527-534 (1994). (Pubitemid 24280108)
14. Erlebacher, A. & Derynck, R. Increased expression of TGF-β 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132, 195-210 (1996).
15. Neptune, E.R. et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407-411 (2003). (Pubitemid 36278859)
16. ?/? mouse. PLoS ONE 5, e10560 (2010).
17. Thiele, F. et al. Cardiopulmonary dysfunction in the osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms. Hum. Mol. Genet. 21, 3535-3545 (2012).
18. McAllion, S.J. & Paterson, C.R. Causes of death in osteogenesis imperfecta. J. Clin. Pathol. 49, 627-630 (1996). (Pubitemid 26264386)
19. Rauch, F., Travers, R., Parfitt, A.M. & Glorieux, F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26, 581-589 (2000). (Pubitemid 30301650)
20. Ward, L.M. et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31, 12-18 (2002). (Pubitemid 34754419)
21. Janssens, K., ten Dijke, P., Janssens, S. & Van Hul, W. Transforming growth factor-β1 to the bone. Endocr. Rev. 26, 743-774 (2005).
22. Fuller, K., Lean, J.M., Bayley, K.E., Wani, M.R. & Chambers, T.J. A role for TGFβ1 in osteoclast differentiation and survival. J. Cell Sci. 113, 2445-2453 (2000). (Pubitemid 30599346)
23. Xian, L. et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 18, 1095-1101 (2012).
24. Alliston, T., Choy, L., Ducy, P., Karsenty, G. & Derynck, R. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 20, 2254-2272 (2001). (Pubitemid 32410595)
25. Edwards, J.R. et al. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J. Bone Miner. Res. 25, 2419-2426 (2010).
26. Sarathchandra, P., Pope, F.M., Kayser, M.V. & Ali, S.Y. A light and electron microscopic study of osteogenesis imperfecta bone samples, with reference to collagen chemistry and clinical phenotype. J. Pathol. 192, 385-395 (2000).
27. Karsdal, M.A. et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 277, 44061-44067 (2002). (Pubitemid 36157833)
28. Gauldie, J. et al. Transfer of the active form of transforming growth factor-β 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. Am. J. Pathol. 163, 2575-2584 (2003). (Pubitemid 37466498)
29. Morty, R.E., Konigshoff, M. & Eickelberg, O. Transforming growth factor-β signaling across ages: from distorted lung development to chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6, 607-613 (2009).
30. Marwick, J.A. et al. Cigarette smoke-induced oxidative stress and TGF-β1 increase p21waf1/cip1 expression in alveolar epithelial cells. Ann. NY Acad. Sci. 973, 278-283 (2002). (Pubitemid 36125020)
31. Hausser, H., Groning, A., Hasilik, A., Schonherr, E. & Kresse, H. Selective inactivity of TGF-β/decorin complexes. FEBS Lett. 353, 243-245 (1994).
32. Keene, D.R. et al. Decorin binds near the C terminus of type I collagen. J. Biol. Chem. 275, 21801-21804 (2000). (Pubitemid 30621746)
33. Marini, J.C. et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 28, 209-221 (2007).
34. Schönherr, E. et al. Interaction of biglycan with type I collagen. J. Biol. Chem. 270, 2776-2783 (1995).
35. Nikitovic, D. et al. The biology of small leucine-rich proteoglycans in bone pathophysiology. J. Biol. Chem. 287, 33926-33933 (2012).
36. Christ, M. et al. Immune dysregulation in TGF-β 1-deficient mice. J. Immunol. 153, 1936-1946 (1994).
37. Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243 (2011).
38. Lonning, S., Mannick, J. & McPherson, J.M. Antibody targeting of TGF-β in cancer patients. Curr. Pharm. Biotechnol. 12, 2176-2189 (2011).
39. Morris, J.C. et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-β (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 11, e90353 (2014).
40. Orwoll, E.S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J. Clin. Invest. 124, 491-498 (2014).
41. Daley, E. et al. Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model. J. Bone Miner. Res. 25, 247-261 (2010).
42. Lin, A.H. et al. Global analysis of Smad2/3-dependent TGF-β signaling in living mice reveals prominent tissue-specific responses to injury. J. Immunol. 175, 547-554 (2005). (Pubitemid 40884361)
43. Abe, M. et al. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216, 276-284 (1994). (Pubitemid 24076008)
44. Chen, Z.H. et al. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc. Natl. Acad. Sci. USA 107, 18880-18885 (2010).
45. Eyre, D. Collagen cross-linking amino acids. Methods Enzymol. 144, 115-139 (1987).